Trial Profile
A Multicenter, Open Label Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects With Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies (The TIDAL Study)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Zandelisib (Primary)
- Indications Follicular lymphoma; Marginal zone B-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms TIDAL
- Sponsors MEI Pharma
- 13 Jun 2023 This trial has been discontinued in Spain (End Date: 24 Mar 2023) according to European Clinical Trials Database record.
- 05 May 2023 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped:discontinuation of zandelisib program.
- 15 Jan 2023 This trial has been discontinued in Austria (End Date: 5 Dec 2022) according to European Clinical Trials Database record.